Results -In the control group ( untreated partners), 20 of 28 (71%) patients had recurrences in six months, versus 17 Moistened swabs were taken of the glans penis/sulcus and anterior urethra of male sex partners for Candida albicans. Samples from partners of infected women were cultured before therapy; after therapy, at intervals which varied according to patient compliance; and at relapse of the female. Patient assessments and cultures were done one to two weeks after treatment, then monthly for one year and when symptomatic recurrences occurred. Recurrence of candidiasis was considered definite if cultures were positive for C. albicans and associated with symptoms or signs of candidiasis. Patients with confirmed recurrence of candida vaginitis were treated with clotrimazole vaginal ovules but the partners were not re-treated.
Student's t test was used to compare the mean patient age for each treatment group; the mean number of candidiasis episodes per year; the mean frequency of intercourse in each group; and the mean number of cultures done for male partners.
Post-treatment infection rates in the patients and rate of oral contraceptive use in each group were analysed by the X square test with Yates's correction, as were all recurrence rates except those at 12 months. Recurrence rates at 12 months and pre-treatment colonisation rates in male partners were analysed using Fisher's exact probability test (2 tailed). Ninety-five percent confidence intervals (CI) were calculated for all results expressed as rates.'R esults The demographic features of the two groups (table 1), were comparable. Of the fifty-eight patients admitted to the study and treated, fifty-four were evaluable. In group 1 (treated partners), two patients dropped out of the study, owing to lack of interest; in group 2 (untreated partners), one patient was removed from the study, after one day treatment, because of a severe adverse reaction to the treatment drug, and one dropped out from disinterest. Sixteen (28%) of the women treated had an adverse reaction to the drug, which was most commonly mild nausea (11/16 or 69%). The one severe reaction involved flush- ing, dizziness and slight blurring of vision associated with weakness. Light headedness and diarrhoea accounted for the remaining reactions.
The initial (pre-treatment) candida colonisation rate for male partners was, for the two groups combined, 7/45 (16%). Individual rates were: 4/23 (17%) for group 1 (CI = 7% to 36%); and 3/22 (14%) for group 2 (CI = 5% to 34%). Post treatment, the penile colonisation with C. albicans was found to be transient and intermittent with some swabs being positive and others negative for yeast in the same patients without further therapy.
Intermittent colonisation rates in the male partners over six months, with C. albicans were 12/26 (46%) in group 1 (CI = 29% to 65%); and 8/26 (31%) in group 2 (CI = 17% to 50%), p = 0-29.
At the end of treatment assessment all patients had resolution of their symptoms, signs and mycological evidence of acute candida vaginitis. At one month, 8/26 (31%) of women in group 1 versus 9/28 (32%) of women in group 2 had recurrence (CI = 17% to 50% and 18% to 51%, respectively, ( This study was designed to detect a 50% difference in relapse rates between the two groups. It is possible that with a larger number of subjects, a small difference in recurrence rates might have been detected. However, I feel that for a potentially minimal difference, routine prophylactic treatment of the male partner would not be worthwhile.
A study by Sobel 6 of women with severe recurrent vulvo-vaginal candidiasis included examining the effect of treating male sexual partners with topical miconazole genital therapy. The treated group had a significantly lower clinical recurrence of symptomatic candida vaginitis during the first six months of followup, but late recurrences at one year were not altered. 
